Business Context and Reporting Period
Corbus Pharmaceuticals Holdings, Inc. is a precision oncology company developing CRB-701, a Nectin-4 antibody-drug conjugate; CRB-601, an anti-integrin monoclonal antibody targeting TGFβ activation; and CRB-913, a peripheral CB1 inverse agonist for obesity. The unaudited Form 10-Q covers the three and nine months ended September 30, 2023, filed November 7, 2023. The company has not generated product revenue and operates as a single development segment.
Financial Performance and Position
| Metric | Q3 2023 | Q3 2022 | 9M 2023 | 9M 2022 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development expense | $6.55 million | $4.11 million | $24.19 million | $9.89 million |
| General and administrative expense | $2.94 million | $4.07 million | $10.79 million | $14.14 million |
| Total operating expenses | $9.49 million | $8.18 million | $34.97 million | $29.04 million |
| Operating loss | $(9.49) million | $(8.18) million | $(34.97) million | $(29.04) million |
| Net loss | $(10.05) million | $(8.78) million | $(36.58) million | $(31.47) million |
| Net loss per share | $(2.27) | $(2.11) | $(8.52) | $(7.55) |
| Net cash used in operating activities | Not provided quarterly | Not provided quarterly | $(30.09) million | $(30.09) million |
Gross profit and operating margins are not meaningful because the company has no revenue. At September 30, 2023, cash and cash equivalents were $11.25 million, investments were $17.48 million, and restricted cash was $0.67 million, for total cash, cash equivalents, investments, and restricted cash of approximately $29.40 million. Management separately cited cash, cash equivalents, and investments of approximately $28.73 million for its liquidity assessment.
Total assets were $36.28 million, compared with $66.31 million at December 31, 2022. Current liabilities were $31.54 million, producing negative working capital of approximately $0.34 million. Total liabilities were $35.97 million, including $17.85 million of current debt. The K2 secured term loan had a principal amount of approximately $18.44 million, plus a $1.59 million final payment, and matures August 1, 2024. The stated interest rate was 13.75% at September 30, 2023.
Investing activities provided $25.25 million during the first nine months, primarily from net sales and maturities of marketable securities. Financing activities used $0.92 million, including debt repayments. The company ended the period with $11.92 million of cash, cash equivalents, and restricted cash, compared with $17.67 million at December 31, 2022.
Material Changes Versus Prior Comparable Period
- Third-quarter research and development expense increased $2.44 million, or approximately 59%, primarily because of higher CRB-601 manufacturing costs, partly offset by lower preclinical study costs.
- Nine-month research and development expense increased $14.29 million, primarily due to the $7.50 million CSPC license payment, a $1.20 million UCSF development milestone, higher CRB-601 manufacturing costs, and increased preclinical and clinical spending.
- General and administrative expense decreased $1.14 million in the quarter and $3.36 million year to date, reflecting lower stock-based compensation, headcount-related salary costs, insurance premiums, consulting costs, and legal expenses.
- The nine-month 2022 period included a $5.00 million litigation settlement with Venn Therapeutics; no comparable settlement expense was recorded in 2023.
- The company completed a 1-for-30 reverse stock split on February 14, 2023. Shares outstanding increased to 4.42 million from 4.17 million at December 31, 2022, principally due to debt conversion, option exercises, and limited at-the-market sales.
- In June 2023, K2 HealthVentures converted $875,000 of debt into 194,444 common shares. The company sold 14,106 shares under its at-the-market facility during the first nine months for approximately $114,000 of gross proceeds.
Guidance, Outlook, Risks, and Unusual Items
Management expects 2023 total expenses to remain generally consistent with 2022, with higher research and development spending as pipeline assets enter clinical development and lower other operating expenses because 2022 legal and settlement costs are not expected to recur. The company expects continued operating losses for at least the next several years.
- CRB-701’s U.S. IND has been cleared, and management planned to begin a U.S. clinical trial in the first quarter of 2024. The program is also being studied in a Phase 1 dose-escalation trial in China.
- Management expected to submit a CRB-601 IND in the fourth quarter of 2023.
- The company states that its cash, cash equivalents, and investments at September 30, 2023 will not fund operating and capital requirements for at least twelve months from the filing date. Management therefore concluded that substantial doubt exists regarding the company’s ability to continue as a going concern.
- Additional financing will be required to fund CRB-701 and CRB-601. Potential sources include equity, convertible or other debt, credit facilities, collaborations, and government grants. Financing may be unavailable or dilutive and may impose restrictive covenants or require the company to surrender valuable rights.
- License obligations include potential milestone payments of up to $130 million in development and regulatory milestones and $555 million in commercial milestones under the CSPC agreement, up to $153.15 million under the UCSF agreement, up to $53 million under the Milky Way agreement, and up to $18.4 million per selected compound under the Jenrin agreement, plus royalties.
- The company identified a material weakness in internal control over financial reporting related to the completeness, accuracy, and timeliness of accruals for licensing upfront payments and issue fees. Disclosure controls were not effective as of September 30, 2023. Management is implementing enhanced reconciliations, analysis, and review procedures but cannot assure successful remediation.
- No material legal proceedings were reported. The filing states that there were no material off-balance-sheet arrangements other than future license-related royalties and milestone obligations.
Important Facts for Investors to Verify
- Confirm the timing, design, enrollment, and funding of the planned CRB-701 U.S. trial and the status of the CRB-601 IND submission.
- Assess available liquidity against the approximately $20.03 million of scheduled K2 principal and final payments, including the substantial 2024 maturities.
- Monitor the company’s ability to raise capital, potential dilution, and any changes to the May 2023 at-the-market offering.
- Review progress in remediating the material weakness and whether subsequent filings report effective disclosure controls.
- Evaluate license milestones, upfront payment obligations, royalties, and the strategic and financial implications of the CSPC, UCSF, Milky Way, and Jenrin agreements.
- Verify the filing’s differing liquidity presentations: approximately $28.73 million of cash, cash equivalents, and investments cited for the going-concern assessment versus approximately $29.40 million when restricted cash is included.